ABCA8: A Potential Drug Target and Biomarker for Organic Anion Transporters

Target Name: ABCA8

NCBI ID: G10351

ABCA8

ABCA8: A Potential Drug Target and Biomarker for Organic Anion Transporters

ABCA8 (ABC-type organic anion transporter) is a member of theABC family of transporters, which are involved in the transport of various anions, including acids, bases, and organic anions. TheABC family has four isoforms, ABCA1, ABCA2, ABCA3, and ABCA4, which are expressed in different tissues and have different functions. ABCA8, also known as ISOFORM 2, is a splice variant of the ABCA1 gene and is predominantly expressed in the liver, kidneys, and heart.

The ABCA8 gene has been extensively studied for its role in various physiological processes, including drug metabolism and transport. Several studies have suggested that ABCA8 may be a drug target or a biomarker for various diseases, including cancer, neurodegenerative diseases, and systemic diseases. In this article, we will explore the potential of ABCA8 as a drug target and biomarker.

Potential Drug Target

ABCA8 has been shown to play a crucial role in drug metabolism and transport in various organisms, including humans. Several studies have demonstrated that alterations in ABCA8 expression levels can affect drug metabolism and pharmacodynamics. For example, studies have shown that ABCA8 is involved in the metabolism of a wide range of drugs, including statins, antidepressants, and anticancer agents.

One of the most significant findings related to ABCA8 and drug metabolism is the role of ABCA8 in the metabolism of statins. ABCA8 is known to be a major transporter of statin-catalyzed 3-hydroxy-3-methylbutyrate (3-HMB), which is a potent metabolite of simvastatin, an commonly prescribed statin drug. ABCA8-deficient mice have higher plasma levels of simvastatin and its metabolite, rosuvastatin, than wild-type mice. These findings suggest that ABCA8 may play a crucial role in the metabolism of statins and that inhibition of ABCA8 may be an effective strategy for increasing the efficacy of these drugs.

Another potential drug target related to ABCA8 is its role in the transport of anticancer agents. ABCA8 has been shown to be involved in the transport of various anticancer agents, including taxanes and camptothecins. ABCA8-deficient mice have reduced sensitivity to these drugs, suggesting that ABCA8 may be a critical determinant of drug response in cancer patients.

Biomarker

ABCA8 has also been suggested as a potential biomarker for various diseases, including cancer. TheABC family of transporters has been shown to be involved in the transport of various biomarkers, including cancer-related antigens, such as the protein Her2 (HER2), which is overexpressed in many types of cancer.

Studies have shown that ABCA8 is involved in the transport of Her2 in various tissues and that its expression levels are regulated by various factors, including cancer-related signaling pathways. ABCA8 has also been shown to play a role in the regulation of Her2 signaling, suggesting that it may be a potential target for cancer therapies that target this pathway.

Conclusion

In conclusion, ABCA8 is a gene that has been extensively studied for its role in various physiological processes, including drug metabolism and transport. The studies suggested that ABCA8 may be a potential drug target or biomarker for various diseases, including cancer. Further research is needed to fully understand the role of ABCA8 in these processes and to develop effective therapies that target this gene.

Protein Name: ATP Binding Cassette Subfamily A Member 8

Functions: Catalyzes ATP-dependent import of organic anions such as taurocholate and estrone sulfate (PubMed:12379217). In vitro, also imports ochratoxin A (PubMed:12379217). Also mediates cholesterol efflux independent of apolipoprotein, and plays a role in sphingomyelin production in oligodendrocytes (PubMed:23560799)

The "ABCA8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABCA8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets